Drug discovery in the ubiquitin-proteasome system - PubMed (original) (raw)
Review
doi: 10.1038/nrd2056.
Affiliations
- PMID: 16816840
- DOI: 10.1038/nrd2056
Review
Drug discovery in the ubiquitin-proteasome system
Grzegorz Nalepa et al. Nat Rev Drug Discov. 2006 Jul.
Abstract
Regulated protein turnover via the ubiquitin-proteasome system (UPS) underlies a wide variety of signalling pathways, from cell-cycle control and transcription to development. Recent evidence that pharmacological inhibition of the proteasome can be efficacious in the treatment of human cancers has set the stage for attempts to selectively inhibit the activities of disease-specific components of the UPS. Here, we review recent advances linking UPS components with specific human diseases, most prominently cancer and neurodegenerative disorders, and emphasize potential sites of therapeutic intervention along the regulated protein-degradation pathway.
Similar articles
- Therapeutic strategies within the ubiquitin proteasome system.
Eldridge AG, O'Brien T. Eldridge AG, et al. Cell Death Differ. 2010 Jan;17(1):4-13. doi: 10.1038/cdd.2009.82. Cell Death Differ. 2010. PMID: 19557013 Review. - Emerging role of the ubiquitin-proteasome system as drug targets.
Kar G, Keskin O, Fraternali F, Gursoy A. Kar G, et al. Curr Pharm Des. 2013;19(18):3175-89. doi: 10.2174/1381612811319180002. Curr Pharm Des. 2013. PMID: 23151131 Review. - Searching for the boundaries: unlimited expansion of ubiquitin and ubiquitin-like signals in multiple cellular functions.
Crosas B, Farràs R, Marfany G, Rodríguez MS, Thomson TM. Crosas B, et al. Biochem Soc Trans. 2010 Feb;38(Pt 1):1-5. doi: 10.1042/BST0380001. Biochem Soc Trans. 2010. PMID: 20074026 - The ubiquitin proteasome system as a potential target for the treatment of neurodegenerative diseases.
Ying Z, Wang H, Wang G. Ying Z, et al. Curr Pharm Des. 2013;19(18):3305-14. doi: 10.2174/1381612811319180013. Curr Pharm Des. 2013. PMID: 23151138 Review. - Strategies for the identification of ubiquitin ligase inhibitors.
Goldenberg SJ, Marblestone JG, Mattern MR, Nicholson B. Goldenberg SJ, et al. Biochem Soc Trans. 2010 Feb;38(Pt 1):132-6. doi: 10.1042/BST0380132. Biochem Soc Trans. 2010. PMID: 20074047 Free PMC article. Review.
Cited by
- Protein homeostasis as a therapeutic target for diseases of protein conformation.
Calamini B, Morimoto RI. Calamini B, et al. Curr Top Med Chem. 2012;12(22):2623-40. doi: 10.2174/1568026611212220014. Curr Top Med Chem. 2012. PMID: 23339312 Free PMC article. Review. - Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).
Wong KM, Micel LN, Selby HM, Tan AC, Pitts TM, Bagby SM, Spreafico A, Klauck PJ, Blakemore SJ, Smith PF, McDonald A, Berger A, Tentler JJ, Eckhardt SG. Wong KM, et al. Invest New Drugs. 2017 Feb;35(1):11-25. doi: 10.1007/s10637-016-0398-8. Epub 2016 Oct 25. Invest New Drugs. 2017. PMID: 27783255 Free PMC article. - Cullin-RING Ligases as attractive anti-cancer targets.
Zhao Y, Sun Y. Zhao Y, et al. Curr Pharm Des. 2013;19(18):3215-25. doi: 10.2174/13816128113199990300. Curr Pharm Des. 2013. PMID: 23151137 Free PMC article. Review. - Erioflorin stabilizes the tumor suppressor Pdcd4 by inhibiting its interaction with the E3-ligase β-TrCP1.
Blees JS, Bokesch HR, Rübsamen D, Schulz K, Milke L, Bajer MM, Gustafson KR, Henrich CJ, McMahon JB, Colburn NH, Schmid T, Brüne B. Blees JS, et al. PLoS One. 2012;7(10):e46567. doi: 10.1371/journal.pone.0046567. Epub 2012 Oct 2. PLoS One. 2012. PMID: 23056346 Free PMC article. - Loss of tumor suppressor NF1 activates HSF1 to promote carcinogenesis.
Dai C, Santagata S, Tang Z, Shi J, Cao J, Kwon H, Bronson RT, Whitesell L, Lindquist S. Dai C, et al. J Clin Invest. 2012 Oct;122(10):3742-54. doi: 10.1172/JCI62727. Epub 2012 Sep 4. J Clin Invest. 2012. PMID: 22945628 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources